Home › SEC Filings › Insider Cluster Activity
Insider Cluster Activity
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONC | CLUSTER | neutral | 3/10 | Director Wang Xiaodong executed a large derivative exercise and sold a substantial block of shares totaling ~$13.4M in o | Sep 10, 2026 |
| TWST | CLUSTER | neutral | 2/10 | Four Twist Bioscience insiders, including CEO Emily Leproust and CAO Robert Werner, sold a total of $473K in open-market | Sep 10, 2026 |
| DNLI | CLUSTER | neutral | 2/10 | Three Denali insiders (COFO, Director, CMO) sold a total of ~$349K in open-market sales over a 5-day window. The aggrega | Sep 10, 2026 |
| TARS | CLUSTER | neutral | 3/10 | Three top insiders (CEO, COO, CMO) sold shares totaling ~$2.5M over a one-week window ending September 4, 2026. The tota | Sep 10, 2026 |
| ARTV | CLUSTER | bearish | 5/10 | A cluster of insider selling at Artiva Biotherapeutics, totaling $477K in open-market sales by the CEO, COO/CLO, CTO, an | Sep 10, 2026 |
| RLAY | CLUSTER | neutral | 4/10 | Two top executives at Relay Therapeutics — CEO Sanjiv Patel and President of R&D Donald Bergstrom — sold a combined $1.0 | Sep 10, 2026 |
| ASND | CLUSTER | neutral | 2/10 | Two Ascendis Pharma insiders sold a combined $873K in shares over a 7-day window, with the bulk ($811K) coming from SVP | Sep 10, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt sold ~$6.4M in open-market shares on the same day United Therapeutics announced a $477.6M accelera | Sep 10, 2026 |
| TRDA | CLUSTER | bearish | 6/10 | Two MPM BioVentures funds (10% owners) sold a combined $547K in TRDA shares over two days, part of a larger 7-day cluste | Sep 9, 2026 |
| BLTE | CLUSTER | bearish | 6/10 | CEO and CFO of Belite Bio sold a combined $837K in open-market sales on Sept 4, 2026, part of a larger 7-day cluster tot | Sep 9, 2026 |
| URGN | CLUSTER | neutral | 2/10 | Two UroGen Pharma insiders — the Chief Medical Officer and General Counsel — sold a combined $102K in open-market shares | Sep 9, 2026 |
| CATX | CLUSTER | neutral | 3/10 | Two 10% owner entities of Perspective Therapeutics (Lantheus Holdings, Inc. and Lantheus Alpha Therapy, LLC) sold a comb | Sep 8, 2026 |
| CYTK | CLUSTER | neutral | 3/10 | Two insiders at Cytokinetics sold a combined $622K in open-market transactions over a week. Director Parshall sold $357K | Sep 8, 2026 |
| UTHR | CLUSTER | neutral | 3/10 | CEO Martine Rothblatt and EVP Paul Mahon executed a cluster of open-market sales totaling ~$6.5M on September 3, 2026, w | Sep 8, 2026 |
| INBX | CLUSTER | bullish | 6/10 | CEO Mark Lappe made a series of open-market purchases totaling ~$2.6M on September 8, 2026, and Director Douglas Forsyth | Sep 8, 2026 |
| MAZE | CLUSTER | bearish | 4/10 | Four top insiders at Maze Therapeutics—CEO, President/R&D/CMO, GC, and CSBO—collectively sold ~$601K in open-market sale | Sep 8, 2026 |
| DYN | CLUSTER | neutral | 3/10 | CEO John Cox and CMO Douglas Kerr sold a total of $131K in DYN shares on September 8, 2026, all at $18.88. The sales are | Sep 8, 2026 |
| MAZE | CLUSTER | neutral | 2/10 | Four top Maze Therapeutics insiders — CEO, President/R&D/CMO, GC, and CSBO — sold a combined ~$498K in open-market share | Sep 5, 2026 |
| ARTV | CLUSTER | neutral | 2/10 | Two C-suite insiders at Artiva Biotherapeutics (COO/CLO and CMO) sold a combined $192K in open-market sales over a 7-day | Sep 5, 2026 |
| CATX | CLUSTER | neutral | 2/10 | Two 10% owner entities (Lantheus Holdings, Inc. and Lantheus Alpha Therapy, LLC) sold a combined ~$243K in open-market t | Sep 5, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt and EVP/General Counsel Paul Mahon sold a combined $1.23M in open-market shares on September 3, 20 | Sep 5, 2026 |
| KRYS | CLUSTER | bearish | 5/10 | Two top executives at Krystal Biotech (CEO Krish S. Krishnan and President of R&D Suma Krishnan) sold a combined ~$12.8M | Sep 4, 2026 |
| DNLI | CLUSTER | neutral | 2/10 | Two Denali Therapeutics insiders (COFO/Secretary Schuth and Director Thornberry) sold a combined $312K in open-market tr | Sep 4, 2026 |
| CATX | CLUSTER | neutral | 3/10 | Two 10% owner entities (Lantheus Holdings and Lantheus Alpha Therapy) sold a combined $491K of CATX shares over two days | Sep 4, 2026 |
| ALEC | CLUSTER | neutral | 3/10 | Three C-suite insiders at Alector (ALEC) sold a total of $285K in open-market sales over a 7-day window, including the C | Sep 4, 2026 |
| MAZE | CLUSTER | neutral | 3/10 | Three top executives at Maze Therapeutics (CEO, President R&D, CSBO) sold a combined ~$1.46M in shares over a three-day | Sep 4, 2026 |
| REGN | CLUSTER | neutral | 2/10 | Two Regeneron insiders (EVP Commercial and a director) sold a total of $1.37M in open-market shares over a three-day win | Sep 4, 2026 |
| TARS | CLUSTER | neutral | 2/10 | CEO Bobak Azamian and CMO Elizabeth Yeu sold a combined $928K in TARS shares over two days. The total represents just 0. | Sep 4, 2026 |
| MAZE | CLUSTER | neutral | 2/10 | Insider cluster at Maze Therapeutics shows CEO Jason Coloma and CSBO Atul Dandekar selling small amounts of stock over a | Sep 4, 2026 |
| ONC | CLUSTER | neutral | 2/10 | Two ONC insiders (PAO Ball and COO Wu) sold a combined $153K in open-market transactions over a one-week window. The clu | Sep 4, 2026 |